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Background: We attempted to identify novel biomarkers and therapeutic targets for esophageal squamous cell
carcinoma by gene expression profiling of frozen esophageal squamous carcinoma specimens and examined the
functional relevance of a newly discovered marker gene, WDR66.
Methods: Laser capture microdissection technique was applied to collect the cells from well-defined tumor areas
in collaboration with an experienced pathologist. Whole human gene expression profiling of frozen esophageal
squamous carcinoma specimens (n = 10) and normal esophageal squamous tissue (n = 18) was performed using
microarray technology. A gene encoding WDR66, WD repeat-containing protein 66 was significantly highly
expressed in esophageal squamous carcinoma specimens. Microarray results were validated by quantitative real-
time polymerase chain reaction (qRT-PCR) in a second and independent cohort (n = 71) consisting of esophageal
squamous cell carcinoma (n = 25), normal esophagus (n = 11), esophageal adenocarcinoma (n = 13), gastric
adenocarcinoma (n = 15) and colorectal cancers (n = 7). In order to understand WDR66’s functional relevance
siRNA-mediated knockdown was performed in a human esophageal squamous cell carcinoma cell line, KYSE520
and the effects of this treatment were then checked by another microarray analysis.
Results: High WDR66 expression was significantly associated with poor overall survival (P = 0.031) of patients
suffering from esophageal squamous carcinomas. Multivariate Cox regression analysis revealed that WDR66
expression remained an independent prognostic factor (P = 0.042). WDR66 knockdown by RNA interference resulted
particularly in changes of the expression of membrane components. Expression of vimentin was down regulated in
WDR66 knockdown cells while that of the tight junction protein occludin was markedly up regulated. Furthermore,
siRNA-mediated knockdown of WDR66 resulted in suppression of cell growth and reduced cell motility.
Conclusions: WDR66 might be a useful biomarker for risk stratification of esophageal squamous carcinomas.
WDR66 expression is likely to play an important role in esophageal squamous cell carcinoma growth and invasion
as a positive modulator of epithelial-mesenchymal transition. Furthermore, due to its high expression and possible
functional relevance, WDR66 might be a novel drug target for the treatment of squamous carcinoma.
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Esophageal squamous cell carcinoma (ESCC) is one of the
most lethal malignancies of the digestive tract and in most
cases the initial diagnosis is established only once the
malignancy is in the advanced stage [1]. Poor survival is
due to the fact that ESCC frequently metastasizes to
regional and distant lymph nodes, even at initial diagnosis.
Treatment of cancer using molecular targets has
brought promising results and attracts more and more
attention [2-5]. Characterization of genes involved in the
progression and development of ESCC may lead to the
identification of new prognostic markers and therapeutic
targets.
By whole genome-wide expression profiling, we found
that WD repeat-containing protein 66 (WDR66), lo-
cated on chromosome 12 (12q24.31), might be a useful
biomarker for risk stratification and a modulator for
epithelial-mesenchymal transition of ESCC.
WD-repeat protein family is a large family found in all
eukaryotes and is implicated in a variety of functions
ranging from signal transduction and transcription
regulation to cell cycle control, autophagy and apoptosis
[6]. These repeating units are believed to serve as a
scaffold for multiple protein interactions with various
proteins [7]. According to whole-genome sequence ana-
lysis, there are 136 WD-repeat proteins in humans
which belong to the same structural class [8]. Among
the WD-repeat proteins, endonuclein containing five
WD-repeat domains was shown to be up regulated in
pancreatic cancer [9]. The expression of human BTRC
(beta-transducing repeat-containing protein), which
contains one F-box and seven WD-repeats, targeted to
epithelial cells under tissue specific promoter in BTRC
deficient (−/−) female mice, promoted the development
of mammary tumors [10]. WDRPUH (WD repeat-
containing protein 16) encoding a protein containing 11
highly conserved WD-repeat domains was also shown
to be up regulated in human hepatocellular carcinomas
and involved in promotion of cell proliferation [11]. The
WD repeat-containing protein 66 contains 9 highly
conserved WD40 repeat motifs and an EF-hand-like
domain. A genome-wide association study identified a
single-nucleotide polymorphism located within intron 3
of WDR66 associated with mean platelet volume [12].
WD-repeat proteins have been identified as tumor
markers that were frequently up-regulated in various
cancers [11,13,14]. Here, we report for the first time that
WDR66 might be an important prognostic factor for
patients with ESCC as found by whole human gene
expression profiling. Moreover, to our knowledge, the
role of WDR66 in esophageal cancer development and
progression has not been explored up to now. To this
end we examined the effect of silencing of WDR66 by
another microarray analysis.In addition, the effect of WDR66 on epithelial-
mesenchymal transition (EMT), cell motility and tumor
growth was investigated.
Methods
Patients
Tissue samples from individuals of the first set (n = 28)
were obtained from the tumor bank of Charité Compre-
hensive Cancer Center. Gene expression was examined
by whole-human-genome microarrays (Affymetrix, Santa
Clara, CA, USA). Ten esophageal squamous cell carcin-
oma (ESCC) and 18 normal esophageal (NE) biopsies
were randomly collected. Normal healthy esophageal
biopsies were collected from patients with esophageal pain
but diagnosed as normal squamous without pathological
changes. Surgical specimens of chemotherapy-naïve pa-
tients with known ESCC of histological grading G1, UICC
stage II and III, had undergone esophagectomy. Patients’
age ranged from 22 to 83 years, with a median age of
59 years.
A second panel (n = 71) consisting of ESCC (n = 25),
NE (n = 11), esophageal adenocarcinoma (EAC) (n = 13),
gastric adenocarcinoma (GAC) (n = 15) and colorectal
cancers (CRC) (n = 7) was used for qRT-PCR validation.
Patients’ age ranged from 24 to 79 years, with a median
age of 63 years.
All samples were snap-frozen in liquid nitrogen and
stored at −80°C. We obtained tissue specimens from all
subjects with informed written consent (approved by the
local ethics committee of the Charité-Universitätsmedizin,
Berlin). Each single specimen included in this study was
histopathologically approved according to grade and stage
by an experienced pathologist ( MV, University Bayreuth).
Laser capture microdissection and microarray
Laser Capture Microdissection (Cellcut, MMI AG and
Nikon TE300 microscope) was used for isolating desired
cells from sections. After transferring 5 μm sections
onto MMI membrane slides, these were fixed in 70%
isopropyl alcohol and then stained with the MMI basic
staining kit. Desired tumor cell or NE areas were se-
lected, cut and collected. Preparation of labeled cRNA
and hybridization were done using the gene chip
hybridization, wash, and stain kit (Affymetrix, Santa
Clara, CA, USA), as described previously [15]. Two
cycle labeling was applied to all samples. In total 28
chip-data were collected using Gene Chip Operation
Software (GCOS, Affymetrix). The 28 specimens
analyzed consists 10 ESCC and 18 NE. To obtain the
relative gene expression measurements, probe set-level
data extraction was performed with the GCRMA
(Robust Multiarray Average) normalization algorithm
implemented in GeneSpring GX10.2 (Agilent). All data
were log2 transformed. A list of all the genes included
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posited in the Gene Expression Omnibus database (http://
www.ncbi.nlm.nih.gov/geo/info/linking.html) under GEO
accession number GSE26886. For gene-by-gene statistical
testing, parametric tests were used to compare differences
between groups. The False Discovery Rate (FDR) was
employed using Benjamini-Hochberg procedure for
multiple testing of the resulting p-value significance.
In situ hybridization
A 148 bp fragment located at the 3 terminal end of
human WDR66 gene (NM144668)was subcloned into
the pBluescript II vector pBS-27.16 using primer pair
forward: 5’-CAACCTgCTCCgTCAAA-3’ and reverse:
5’-TAAACATTCCTggTAACTTCAC-3’. The linearized
plasmid was used as a template for the synthesis of anti-
sense probes. The probe was labeled by digoxigenin / dUTP
with a DIG/RNA labelling kit (Boehringer Mannheim),
according to the manufacturer’s instructions. The quality
and quantity of the probe were confirmed by gel electro-
phoresis before used for In situ hybridization. The
Digoxigenin-labeled probe was applied to 5 μm dewaxed
FFPE sections and hybridized at 65°C overnight in a
humid chamber. After 3 washes to remove the nonspecific
binding or unbound probes, digoxigenin-labeled probe
was detected using the alkaline phosphatase method.
RNA extraction and qRT-PCR
RNA extractions were carried out using the RNeasy Mini
Kit (Qiagen, Valencia, CA, USA). Total RNA quality and
yield were assessed using a bioanalyzer system (Agilent
2100 Bioanalyzer; Agilent Technologies, Palo Alto, CA,
USA) and a spectrophotometer (NanoDrop ND-1000;
NanoDrop Technologies, Wilmington, DE, USA). Only
RNA with an RNA integrity number > 9.0 was used for
microarray analysis.
For quantification of mRNA-expression, qRT-PCR was
performed for 3 genes plus one control, using pre-
designed gene-specific TaqManW probes and primer sets
purchased from Applied Biosystems (Hs01566237_m1
for WDR66, Hs00958116_m1 for VIM, Hs00170162_m1
for OCLD, and 4326317E for GAPDH). Conditions and
data analysis of qRT-PCR were as described [16].
Cell culture and siRNA-mediated knockdown
KYSE520, OE33, SW480, Caco2, HCT116, HT29, HL60,
LS174T, Daudi, HEK293, MCF7, MDA-MB-231, MDA-
MB-435 and Capan-I were obtained from the American
Type Culture Collection (ATCC, Manassas, VA) and
cultured according to the supplier’s instructions. For
siRNA-mediated knockdown of WDR66, cells were
seeded in 6-well plates on the day before transfection.
On day 0, cells were transfected with siRNA at 25 nmol/L
concentrations using Thermo Scientific DharmaFECTtransfection reagents according to manufacturer’s in-
structions. The siRNA sense 5’ – GuuACuAAAGGu
GAGCAuA - 3’ sequence corresponding to WDR66
mRNA was chemically synthesized by sigma-Proligo
(Munich, Germany). RNA was extracted at indicated
time points as described.
Microarray analysis of WDR66 knock-down cells
Total RNA was extracted from 106 cell pellet using
RNeasy Mini Prep Kit (Qiagen, Hilden, Germany). RNA
quality was checked by Bioanalyzer (Agilent, Santa Clara,
CA) Only RNA samples showing a RIN of at least 9.0
were used for labelling. Total RNA (1 μg) was labelled
with Cy3 using the Low Input RNA Amplification Kit
(Agilent, Santa Clara, CA). Labelled cRNAs were hybrid-
ized to Whole Human Genome 4x44K Oligonucleotide
Microarrays (Agilent, Santa Clara, CA) according to the
manual. Arrays were scanned by using standard Agilent
protocols and a G2565AA Microarray Scanner (Agilent,
Santa Clara, CA). Raw expression values were determined
using Feature Extraction 9.0 software (Agilent, Santa
Clara, CA).
Western blotting analysis
Total cell extracts were obtained and cell lysate containing
50 μg of protein was separated on 10% SDS-polyacrylamide
gel and then blotted onto polyvinylidene difluoride (PVDF)
membranes (Millipore, Bedford, MA, USA). Primary
antibody for vimentin detection was mouse monoclonal
anti-human vimentin antibody (Sigma-Aldrich Corpor-
ation, V5255, 1:200, approximately 54 kDa). Primary
antibody for occludin detection was rabbit polyclonal
anti-human occludin antibody (Invitrogen, 71–1500,
1:500, at 65 kDa). ß-actin was used as loading control
(Abcam, 1:2000, ab8226). Signals were detected using
ECL kit (Amersham Pharmacia Biotech, Piscataway, NJ,
USA). Images were scanned by FujiFilm LAS-1000
(FujiFilm, Düsseldorf, Germany).
Cell number, cell motility and wound-healing assay
Cells were seeded in 6-well plates 24 h before transfection.
Transfection was done as described above. Cells were
collected at indicated time points, and cell numbers were
measured using POLARstar Omega reader (BMG
Labtech, Offenburg, Germany). Emission and excitation
filters were 485 and 520 nm. The results were analyzed by
MARS data analysis software. Cell motility was deter-
mined using 12-well Transwell Permeable Support inserts
with polycarbonate filters with a pore size of 8 μm
(Corning Costar, Lowell, MA), according to the manufac-
turer’s instructions. Wound healing assays were performed
in triplicates using cytoselect 24-well wound healing assay
(Cell Biolabs, Inc.).
Figure 1 (See legend on next page.)
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Figure 1 WDR66 is highly expressed in esophageal squamous cell carcinoma. A: mRNA expression of the WDR66 gene was determined by
microarray analysis. Microarray analysis was performed on 18 healthy normal esophageal epithelium (NE) and 10 esophageal squamous cell
carcinoma (ESCC) samples. Gene expression is presented as normalized (log2 scale) signal intensity of the WDR66 gene. The WDR66 gene is
significantly differentially expressed in ESCC (corrected p-value < 0.0001). Expression level of WDR66 gene is low in NE but high in ESCC cases.
B: Relative mRNA expression of the WDR66 gene in an independent validation cohort. Quantitation was done relative to the transcript of GAPDH.
Significance in differential expression of individual gene between groups was calculated (p-value < 0.001). Results showed that WDR66 gene
expression level is highest in ESCC and low to absent in NE or other carcinomas. On the horizontal axis patient groups ESCC, NE, EAC, GAC and
CRC are depicted. C: WDR66 gene is highly expressed in ESCC epithelium according to in situ hybridization. In situ hybridization was down using
anti-sense probes of human WDR66 gene in FFPE sections of esophageal specimens. Signals for WDR66 transcripts were observed specifically in
esophageal squamous cell carcinoma (ESCC, right), but not in normal squamous epithelium (NE, left). D: WDR66 expression level in various
human cell lines. WDR66 expression was examined by quantitative real-time PCR in 14 cell lines cultivated from different human carcinomas. The
expression was quantified relative to human esophageal squamous carcinoma cell line KYSE520. E: Tissue-specific expression of WDR66 gene in
various human normal tissues. Quantitative real-time PCR analysis of WDR66 expression levels in 20 human normal tissues (FirstChoiceW Human
Total RNA Survey Panel). WDR66 gene is preferentially expressed in testis. Gene level was quantified relative to the expression in ESCC cell
line KYSE520.
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Statistical analysis was done using GraphPad Prism
version 5 for Windows (GraphPad Software) and SPSS
version 13 for Windows (SPSS, Chicago, IL, USA) as
follows: GraphPad Prism, Unpaired t test with Welch’s
correction of quantitative real-time RT-PCR measurements
of WDR66 in patient samples and of gene expression
measurements in the validation cohort; nonparametric
Mann–Whitney U test of cell numbers, motility assay, and
cell wound assay after knockdown of WDR66; SPSS,
Kaplan-Meier survival analysis and log-rank statistics, cut-
point analysis of qRT-PCR measurements of WDR66 in
patient samples using maximally selected rank statistics to
determine the value separating a group into two groups
with the most significant difference when used as a cut-
point; grouping of patients according to median of qRT-
PCR measurements was done as follows: WDR66 ≤ 125,
WDR66 low; WDR66 > 125, WDR66 high; the stratified
Cox-regression model was used to determine prognostic
factors in a multivariate analysis with WDR66 dichoto-
mized at the previously determined cut-points.
Results
WDR66 is specifically highly expressed in esophageal
squamous cell carcinoma
Whole genome-wide expression profiling was performed
on 28 esophageal specimens (GSE26886). To make sure
that only epithelial cells were studied, we applied laser
capture microdissection technique to the specimens. A
number of genes differentially expressed between ESCC
samples and normal esophageal squamous epithelium
samples were identified. The probe set with the highest
fold change and lowest p-value represented the WDR66
transcript (P < 0.0001) (Figure 1A). As a validation study,
WDR66 expression was examined by qRT-PCR in an
independent cohort consisting of 71 specimens including
ESCC (n = 25), NE (n = 11), EAC (n = 13), GAC (n = 15)
and CRC (n = 7). We found that WDR66 was highly
expressed in 96% of ESCC patients (Figure 1B).Confirming our previous results from the microarray
study, WDR66 expression was found to be significantly
higher in ESCC compared to NE as well as the other three
cancer types checked in this cohort (P < 0.0001). Immuno-
histochemical localization of WDR66 was not carried out
because none of the WDR66 antibodies available allowed
detecting a specific protein band on Western blots. The
presence of WDR66-specific mRNA was probed by in-situ
hybridization using single-stranded RNA probes of the
WDR66 gene in 4% PFA-fixed paraffin-embedded esopha-
geal tissues. WDR66 transcription (positive staining)
was specifically detected in the esophageal squamous
carcinoma cells but not in normal squamous epithelia
(Figure 1C). Furthermore, WDR66 expression was exam-
ined in 14 human cell-lines and 20 normal human tissues
by qRT-PCR. Expression of WDR66 gene was abundantly
expressed only in the human esophageal squamous cell
carcinoma cell line KYSE520, but not expressed in any
other human cell line, such as OE33, SW480, HT29,
HCT116, LS174T, Caco2, HL60, HEK293, Daudi, Capan1,
MCF7, MDA-MB231 and MDA-MB435 (Figure 1D).
Among 20 normal human tissues examined by qRT-PCR,
WDR66 was most abundantly expressed in the testis
(Figure 1E). Thus, our data suggest that WDR66 might be
a cancer / testis antigen.
High expression of WDR66 correlates with poor survival
outcome in ESCC
In order to test if WDR66 expression correlates with
prognostic markers in a separate validation set of ESCC
examples, we determined WDR66 expression in an in-
dependent set of n = 25 ESCC examples using qRT-PCR
(Additional file 1: Table S1). High expression of WDR66
RNA was found to be a significant prognostic fac-
tor with regard to cancer-related survival (P = 0.031;
Figure 2). When analyzed with regard to various clinico-
pathological parameters, such as gender (P = 0.804), age
(P = 0.432), tumor differentiation (P =0.032), pT factor
(P = 0.234), lymph node metastasis (P = 0.545), distant
Figure 2 High WDR66 mRNA expression is associated with poor survival in ESCC patients. Kaplan-Meier analysis of survival of grouped
according to WDR66 expression as measured by quantitative real-time RT-PCR. Grouping of patients according to median of qRT-PCR
measurements was done as follows: WDR66≤ 125, WDR66 low (n = 12); WDR66 > 125, WDR66 high (n = 13). After choosing an optimal cut-point,
analysis for WDR66 was done using maximally selected rank statistics. The group with patients expressing WDR66 at low levels showed a
significantly better overall survival compared with the group with high levels of WDR66 expression (P = 0.031; log rank).
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multivariate Cox regression analysis revealed that WDR66
expression remained an independent prognostic factor
(P = 0.042; Table 1).
Knockdown of WDR66 in KYSE520 effected VIM and OCLD
expression in vitro
In order to learn more about the function of WDR66,
RNA interference was used to silence its expression in
KYSE520 cells, a human esophageal squamous cellTable 1 Cox regression analysis for factors possibly
influencing disease-specific survival in patients with ESCC
in our cohort
Variables Hazard ratio 95% CI P
WDR66 (high vs low) 2.644 1.034-6.758 0.042
Gender (male vs female) 1.15 0.380-3.48 0.804
Age, y (<60 vs ≥60) 1.46 0.569-3.748 0.432
Tumor differentiation
(high grade vs low or
Intermediate grade)
2.763 1.093-6.983 0.032
pT factor
( pT3 or pT4 vs pT1 or pT2)
2.133 0.613-7.420 0.234
Lymph node metastasis
(yes vs no)
1.575 0.362-6.852 0.545
Distant metastasis (yes vs no) 1.376 0.492-3.846 0.543
TNM stage (I or II vs III or IV) 7.711 2.181-27.259 0.002carcinoma cell line which highly expressed WDR66. Sub-
sequently, a microarray expression analysis was performed
in order to identify the genes affected by WDR66 knock-
down. A total of 699 genes was identified based on a
two-fold change expression difference with p-value of
p < 0.001. In an approach to link the observed gene ex-
pression profile to gene function, these 699 differentially
expressed genes were subjected to gene ontology (GO)
analysis. Functional enrichment analysis identified 10
GO terms to be significantly associated with the
WDR66 knockdown (Additional file 2: Table S2). All
these 10 GO terms are membrane related. We checked
the expression of vimentin and occludin in ESCC pa-
tients of our cohort, and found that vimentin was highly
expressed (p = 0.0008) while occludin was less expressed
(p < 0.0001) in ESCC specimens in comparison to NE
(Figure 3A). Microarray data were validated by qRT-
PCR and Western blotting providing independent evi-
dence of the changes of vimentin (VIM) and occludin
(OCLD) expression associated with the WDR66 knock-
down (Figure 3B, 3C).
Knockdown of WDR66 in KYSE520 cells affects cell
motility and results in growth suppression
Due to the effect of WDR66 on the expression of
vimentin, an important EMT marker which plays a central
role in the reversible trans-differentiation and occludin, an
adhesion molecules that is a constituent of tight junctions,
Figure 3 Knockdown of WDR66 gene affects expression of vimentin and occludin. A: mRNA expression of the VIM and OCLN gene in the
original training cohort determined by microarray analysis. Array data analysis was performed on 18 healthy normal esophageal epithelium (NE)
and 10 esophageal squamous cell carcinoma (ESCC) samples. Gene expression is presented as normalized (log2 scale) signal intensity of the
genes of interest. VIM and OCLN are significantly differentially expressed in ESCC compared with NE (corrected p-value: VIM p = 0.0008; OCLD
p < 0.0001). VIM expression level is low in NE but high in ESCC cases, whereas OCLN expression is high in NE but low in ESCC cases. The
horizontal axis depicts the patient groups ESCC and NE. (∗∗∗ P < 0.001) B: Knockdown of WDR66 affects mRNA expression of VIM and OCLN.
Gene expression is presented as normalized (log scale) signal intensity for mRNA expression levels of VIM and OCLN gene. Gene expression level
of VIM was significantly down regulated whereas OCLN expression was significantly higher in cells treated with WDR66 siRNA in comparison to
NTC (KYSE520) and Allstar (negative control siRNA) (corrected p-value: VIM p = 0.0286; OCLD p = 0.0186). Data are representatives of four
independent experiments. (∗p < 0.05). C: Detection of vimentin and occludin protein by immunoblotting of KYSE520 cells treated with WDR66
siRNA in comparison to NTC (KYSE520) and Allstar (negative control siRNA). β-actin was used as loading control. Vimentin expression was
significantly down regulated while occludin was significantly higher expressed in cells treated with WDR66 siRNA.
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esophageal squamous cancer cells. WDR66 was silenced
in the human squamous cell carcinoma cell line KYSE520
by RNA interference. Transfection efficiency was evalu-
ated by qPCR. Cell migration assays showed that KYSE520
cells, which had been transfected with WDR66 siRNA,
displayed a motility capacity of only 40% compared to the
cells having been transfected with control siRNA (AllStar)
after 16 hours (Figure 4A). Moreover, we found that intro-
duction of siWDR66 remarkably suppressed growth of
KYSE520 in comparison to control cells (Figure 4B). In
order to visualize the involvement of WDR66 in cell
migration and proliferation, a wound-healing assay was
carried out. The insert was removed at defined time points
of scratching and the results were recorded by taking
pictures (Figure 4C). Thus, our data suggest that WDR66
promotes cell proliferation and affects cell motility.Discussion
By whole genome-wide expression profiling we found
that WD repeat-containing protein 66 (WDR66) might
be a useful biomarker for risk stratification and a modu-
lator for epithelial-mesenchymal transition of ESCC.
Among 20 normal human tissues examined by qRT-
PCR, WDR66 was most abundantly expressed in the
testis. Thus, our data suggest that WDR66 might be a
cancer / testis antigen. Cancer-testis (CT) genes, nor-
mally expressed in germ line cells but also activated in a
wide range of cancer types, often encode antigens in
cancer patients [17]. Testis is an immune-privileged site
as a result of a blood barrier and lack of HLA class I
expression on the surface of germ cells [18]. Hence, if
testis-specific genes are expressed in other tissues, they
can be immunogenic. Expression of some cancer-testis
genes in a high percentage of esophageal tumors makes
Figure 4 Knockdown of WDR66 gene affects cell motility and cell growth. A: Cell motility assays showed that knockdown of WDR66
reduced cell migration after 16 hours. About 35% of the siWDR66 cells were migrated in comparison to that of the mock control cells. The
differences between siWDR66 and Allstar (negative control siRNA) cells were significant (p = 0.0032) using the paired t test. The data shown are
representatives of three independent experiments and each done in quadruplicate. B: Knockdown of WDR66 leads to suppression of cell growth.
A total of 1.5×104 cells were seeded at day 0. WDR66 knockdown cells grew slower than cells treated with Allstar (negative control siRNA). The
differences between siWDR66 and Allstar (negative control siRNA) treated cells were highly significant (p = 0. 0098). C: Wound-healing assays
show that knockdown of WDR66 reduces cell motility. Representative images are shown. Images are taken immediately after insert was removed
and 8 hours later. Original magnification is x400.
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MAGE-A4 and NY-ESO-1 [19]. NY-ESO-1 is a highly
immunogenic, prototypical protein marker limited in
expression to a wide variety of cancer types but not in
normal tissue, with the exception of the immune-
privileged testes, and has been heavily investigated as
target for immunotherapy in cancer patients. Recently,
immunotherapy of various cancers again NY-ESO-1
showed promising clinical results [20-22]. Unfortu-
nately, most cancer / testis antigens are expressed only
in a small group of tumor patients, among 10-40%.
However, we found that the expression of WDR66 was
specifically enhanced in 96% of ESCC patients and also
very low or absent in normal tissues. WDR66 may be a
novel Immunotherapy target for ESCC.
Our experiments revealed a strong association of
WDR66 expression with vimentin and occludin. Vimentin
is an important mesenchymal marker and plays a central
role for reversible trans-differentiation [23]. Tumor cells
undergoing EMT have an increased the ability for detach-
ment from the main tumor bulk, which is a crucial stepfor tumor dissemination and metastasis [24]. EMT is
accompanied by a switch from keratin to vimentin ex-
pression [25]. Earlier studies also demonstrated a correl-
ation between the reduction of tight junctions and
tumor metastasis. Here, we found a decreased expres-
sion of occludin, an important tight junction protein.
According to a recent study comparing the risk of
metastasis in ESCC and EAC, ESCC is characterized by
a more aggressive behavior and tendency for early
metastasis [26]. Thus, we hypothesize that the elevated
expression of WDR66 in ESCC may promote EMT
through an up-regulation of vimentin expression and a
down regulation of occludin and cohesion of the tumor
tissue. At this point, we checked the expression of
vimentin and occludin in ESCC patients of our cohort,
and found that vimentin was highly expressed while
occludin was less expressed in ESCC specimens in com-
parison to NE which supports our hypothesis. A recent
study showed that low expression of the tight junction
protein claudin-4 is associated with poor prognosis in
ESCC [27]. This is also in agreement with the results of
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significantly less expressed in ESCC and also remarkably
over expressed after WDR66 knockdown (data not
shown).
Conclusions
In summary, we have identified WDR66 as a potential
novel prognostic marker and promising target for
ESCC. This result is based on our observations that (1)
WDR66 is specifically highly expressed in esophageal
squamous cell carcinoma and high WDR66 expression
correlates with poor overall survival, (2) WDR66 regu-
lates vimentin and occludin expression and plays a cru-
cial role for EMT, and (3) knockdown of WDR66
suppresses cell growth and motility and decreases cell
viability of ESCC cells. Therefore, we propose that
WDR66 plays a major role in ESCC biology. Our func-
tional data furthermore warrants further investigation
of selective targeting of WDR66 as a novel drug target
for ESCC treatment.
Additional files
Additional file 1: Table S1. The clinicopathologic characterization of
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Additional file 2: Table S2. Significantly enriched Gene Ontology (GO)
terms identified for genes differentially expressed in siWDR66 Kyse520
cells. GO analysis was performed using GeneSpring. The 10 GO terms
with the significant corrected P-value (FDR false discovery rate corrected
for multiple testing) are depicted sorted by p-Value (noncorrected).
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